Journal of Hepatology
Volume 48, Issue 1 , Pages 35-42 , January 2008

Treatment of hepatitis C virus in human immunodeficiency virus infected patients in “real life”: Modifications in two large surveys between 2004 and 2006

  • Patrice Cacoub

      Affiliations

    • Université Pierre et Marie Curie-Paris 6, CNRS, UMR 7087, Paris, F-75013, France
    • AP-HP, Hôpital Pitié-Salpêtrière, Service de Médecine Interne, Paris, France
    • Corresponding Author InformationCorresponding author. Address: AP-HP, Hôpital Pitié-Salpêtrière, 83 boulevard de L’Hopital 75013 Service de Médecine Interne, Paris, France. Tel.: +33 1 42 17 80 27; fax: +33 1 42 17 80 33.
    • ,
  • Philippe Halfon

      Affiliations

    • Laboratoire Alphabio, Marseille, France
    • ,
  • Eric Rosenthal

      Affiliations

    • Service de Médecine Interne, Hôpital de l’Archet, Nice, France
    • ,
  • Gilles Pialoux

      Affiliations

    • Service de Maladies Infectieuses, Hôpital Tenon, Paris, France
    • ,
  • Yves Benhamou

      Affiliations

    • Service d’Hépatogastroentérologie, Hôpital de la Pitié-Salpêtrière, Paris, France
    • ,
  • Christian Perronne

      Affiliations

    • Service de Maladies Infectieuses, Hôpital Raymond Poincaré, Garches, France
    • ,
  • Stanislas Pol

      Affiliations

    • Service d’Hépatologie, Hôpital Cochin, Université René Descartes Paris V and INSERM U567, Paris, France
    • ,
  • Prospecth Study Group

      Affiliations

    • Prospecth Study Group list members at the end.

Received 10 May 2007 ,Revised 3 July 2007 ,Accepted 19 July 2007.

References 

  1. Cacoub P, Geffray L, Rosenthal E, Perronne C, Veyssier P, Raguin G, et al. Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French departments of internal medicine/infectious diseases, in 1995 and 1997. Clin Infect Dis. 2001;32:1207–1214
  2. Rosenthal E, Poirée M, Pradier C, Perronne C, Salmon-Ceron D, Geffray L, et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS. 2003;17:1803–1809
  3. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;32:492–497
  4. Jaggy C, von Overbeck J, Ledergerber B, Schwarz C, Egger M, Rickenbach M, et al. Mortality in the Swis Mortality in the Swiss HIV cohort study (SHCS) and the Swiss general population. Lancet. 2003;362:877–878
  5. Tedaldi EM, Baker RK, Moorman AC, Alzola CF, Furhrer J, McCabe RE, et al. Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. Clin Infect Dis. 2003;36:363–367
  6. Martin-Carbonero L, Soriano V, Valencia ME, Lopez M, Gonzalez-Lahoz J. Impact of chronic viral hepatitis on hospital admission and mortality in HIV-infected patients. AIDS Res Hum Retroviruses. 2001;17:1467–1471
  7. Lewden C, Salmon D, Morlat P, Bevilacqua S, Jougla E, Bonnet F, et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol. 2005;34:121–130
  8. Rosenthal E, Pialoux G, Bernard N, Pradier C, Rey D, Bentata M, et al. Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group (MORTAVIC 2003 Study). J Viral Hepatol. 2007;14:183–188
  9. Sherman KE, Rouster SD, Chung RT. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US Adult AIDS Clinical Trials Group. Clin Infect Dis. 2002;34:831–837
  10. Anonymous. Premiers résultats du nouveau dispositif de surveillance de l’infection à VIH et situation du sida au 30 September 2003. BEH 2004;24–25:102–109.
  11. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339:1485–1492
  12. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 1998;352:1426–1432
  13. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med. 1998;339:1493–1499
  14. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–965
  15. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982
  16. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346–355
  17. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. PEG-interferon-alfa-2a plus ribavirin versus interferon-alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-co-infected persons. N Engl J Med. 2004;351:451–459
  18. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al. Peginterferon-alfa-2a plus ribavirin versus interferon-alfa-2a plus ribavirin in HIV-infected patients. N Engl J Med. 2004;351:438–450
  19. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, et al. A randomized controlled trial of pegylated interferon alfa-2b plus ribavirin versus standard interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C in HIV-infected patients (RIBAVIC-ANRS HC02). JAMA. 2004;292:2839–2848
  20. Laguno M, Murillas J, Blanco JL, Martinez E, Miquel R, Sanchez-Tapias JM, et al. Peginterferon-alfa-2b plus ribavirin versus interferon-alfa-2b plus ribavirin for treatment of HIV–HCV co-infected patients. AIDS. 2004;18:F27–F36
  21. Fleming CA, Craven DE, Thornton D, Tumilty S, Nunes D. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis. 2003;36:97–100
  22. Fleming CA, Tumilty S, Murray JE, Nunes D. Challenges in the treatment of patients coinfected with HIV and hepatitis C virus: need for team care. Clin Infect Dis. 2005;40:S349–S354
  23. Cacoub P, Rosenthal E, Halfon P, Sene D, Perronne C, Pol S. Treatment of hepatitis C virus and human immunodeficiency virus coinfection: from large trials to real life. J Viral Hepatol. 2006;13:678–682
  24. Alberti A, Clumeck N, Collins S, Gerlich W, Lundgren J, Palu G, et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol. 2005;42:615–624
  25. Maida I, Soriano V, Ramos B, Rios P, Gonzalez-Lahoz J, Nunez M. Characteristics and prospects for hepatitis C therapy of an HIV–HCV coinfected population followed at a reference HIV center. HIV Clin Trials. 2005;6:329–336
  26. Mehta SH, Lucas GM, Mirel LB, Torbenson M, Higgins Y, Moore RD, et al. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS. 2006;20:2361–2369
  27. Nunes D, Saitz R, Libman H, Cheng DM, Vidaver J, Samet JH. Barriers to treatment of hepatitis C in HIV/HCV-coinfected adults with alcohol problems. Alcohol Clin Exp Res. 2006;30:1520–1526
  28. Cooper CL, Cameron DW. Effect of alcohol use and highly active antiretroviral therapy on plasma levels of hepatitis C virus (HCV) in patients coinfected with HIV and HCV. Clin Infect Dis. 2005;41:S105–S109
  29. Edlin BR, Kresina TF, Raymond DB, Carden MR, Gourevitch MN, Rich JD, et al. Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin Infect Dis. 2005;40:S276–S285
  30. Seydi M, Morlat P, Bonnet F, Rambeloarisoa J, Bernard N, Lacoste D, et al. Efficacy and safety of pegylated-interferon plus ribavirin in HIV-infected patients co-infected with hepatitis C virus in clinical practice: a 32 cases observational follow-up. Rev Med Intern. 2005;26:280–287
  31. Tien PC. Management and treatment of hepatitis C virus infection in HIV-infected adults: recommendations from the veterans affairs hepatitis C resource center program and national hepatitis C program office. Am J Gastroenterol. 2005;100:2338–2354
  32. Scheft H, Fontenette DC. Psychiatric barriers to readiness for treatment for hepatitis C Virus (HCV) infection among injection drug users: clinical experience of an addiction psychiatrist in the HIV–HCV coinfection clinic of a public health hospital. Clin Infect Dis. 2005;40:S292–S296
  33. Myers RP, Benhamou Y, Imbert-Bismut F, Thibault V, Bochet M, Charlotte F, et al. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. AIDS. 2003;17:721–725
  34. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317–1325
  35. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128:343–350
  36. Clanon KA, Johannes Mueller J, Harank M. Integrating treatment for hepatitis C virus infection into an HIV clinic. Clin Infect Dis. 2005;40:S362–S366
  37. Anonymous. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002;19:1–46.
  38. Soriano V, Puoti M, Sulkowski M, Mauss S, Cacoub P, Cargnel A, et al. Care of patients with hepatitis C and HIV coinfection. AIDS. 2004;18:1–12
  39. Neff GW, Shire NJ, Rudich SM. Outcomes among patients with end-stage liver disease who are coinfected with HIV and hepatitis C virus. Clin Infect Dis. 2005;41:S50–S55

☆ The authors declare that they do not have anything to disclose regarding funding or conflict of interest with respect to this manuscript. PH is an employee of Laboratoire Alphabio, Marseille, France.

PII: S0168-8278(07)00511-9

doi: 10.1016/j.jhep.2007.07.028

Journal of Hepatology
Volume 48, Issue 1 , Pages 35-42 , January 2008

Article Tools